Abstract
Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Current Drug Delivery
Title: Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Volume: 8 Issue: 1
Author(s): Hong Song and George Sgouros
Affiliation:
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Abstract: Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Export Options
About this article
Cite this article as:
Song Hong and Sgouros George, Radioimmunotherapy of Solid Tumors: Searching for the Right Target, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663651
DOI https://dx.doi.org/10.2174/156720111793663651 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit
Current Radiopharmaceuticals MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
CNS & Neurological Disorders - Drug Targets Polo-Like Kinases Inhibitors
Current Medicinal Chemistry Clinical Application of Percutaneous Puncture Biopsy Guided by Fused and 3D-reconstructed PET/CT Images
Current Medical Imaging Nano-Based Therapy for Treatment of Skin Cancer
Recent Patents on Anti-Infective Drug Discovery Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins
Recent Patents on Anti-Infective Drug Discovery HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
Cardiovascular & Hematological Disorders-Drug Targets